Global Biosimilars Market Regulations Sales Revenue Clinical Trials Pipeline Report

The evolution of biosimilars has currently reached different stages across the world. Owing to variable clarity in the guidelines and diverse regulatory pathways, various definitions of biosimilars (or the broader group of follow-on biologics) have emerged across countries. Till now the European region has the best-established framework for biosimilars. The US is currently almost aligned to the European standards. Biosimilars are also known as follow on biologics in the US and subsequent entry biologics in Canada, are biologic products which are approved in a country, which has an abbreviated approval process for biologic products which references an originator biologic in the regulatory submission.

Download Report:

https://www.kuickresearch.com/report-Global-Biosimilars-Market-Regulations-&-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Global Biosimilars Market Regulations & Pipeline Insight" Table of Contents

1. Global Biosimilars Market Outlook
1.1 Market Overview
1.2 Clinical Pipeline Insight

2. Global Biosimilars Market Dynamics
2.1 Favorable Market Parameters
2.2 Issues to be Discussed

3. Global Biosimilars Market Future Growth Opportunities

4. Regulatory Pathways for Development & Marketing of Biosimilars
4.1 Australia
4.2 Canada
4.3 Europe
4.4 Japan
4.5 India
4.6 Malaysia
4.7 Saudi Arabia
4.8 Singapore
4.9 South Africa
4.10 South Korea
4.11 Turkey
4.12 US

5. Global Biosimilars Pipeline by Phase, Indication, Company & Country
5.1 Unknown
5.2 Research
5.3 Preclinical
5.4 Clinical
5.5 Phase-0
5.6 Phase-I
5.7 Phase-I/II
5.8 Phase-II
5.9 Phase-III
5.10 Preregistration
5.11 Registered

6. Marketed Biosimilars by Indication, Company & Country

7. Suspended & Discontinued Biosimilars Pipeline by Phase, Indication, Company & Country
7.1 No Development Reported
7.2 Discontinued
7.3 Suspended

8. Competitive Landscape
8.1 Actavis
8.2 Amgen
8.3 BioXpress Therapeutics
8.4 Boehringer Ingelheim
8.5 Biocon
8.6 Bio Sidus
8.7 Dong-A Pharmaceutical
8.8 Harvest Moon Pharmaceuticals
8.9 Inbiopro Solutions
8.10 Mylan
8.11 Reliance Life Sciences
8.12 Sandoz International

Figure 1-1: Global Biosimilars Market (US$ Billion), 2013-2018
Figure 1-2: Global Biosimilars Market by Segment (%), 2018
Figure 1-3: Global Biosimilars Clinical Pipeline by Phase (%), 2014
Figure 1-4: Global Biosimilars Clinical Pipeline by Phase (Number), 2014
Figure 1-5: No Development Reported in Biosimilars Clinical Pipeline by Phase (%), 2014
Figure 1-6: No Development Reported in Biosimilars Clinical Pipeline by Phase (Number), 2014
Figure 1-7: Discontinued Biosimilars in Clinical Pipeline by Phase (%), 2014
Figure 1-8: Discontinued Biosimilars in Clinical Pipeline by Phase (Number), 2014
Figure 7-1: Biocon Biosimilars Pipeline
Figure 7-2: Harvest Moon Pharmaceuticals Biosimilars Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.